Current Report Filing (8-k)
June 27 2022 - 4:02PM
Edgar (US Regulatory)
0001788028
false
0001788028
2022-06-23
2022-06-23
0001788028
JSPR:VotingCommonStockParValue0.0001PerShareMember
2022-06-23
2022-06-23
0001788028
JSPR:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member
2022-06-23
2022-06-23
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): June 23, 2022
JASPER
THERAPEUTICS, INC.
(Exact
Name of Registrant as Specified in its Charter)
Delaware |
|
001-39138 |
|
84-2984849 |
(State
or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
2200
Bridge Pkwy Suite #102
Redwood City, California 94065
(Address
of Principal Executive Offices) (Zip Code)
(650)
549-1400
Registrant’s
telephone number, including area code
N/A
(Former
Name, or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Exchange Act:
(Title of each class) |
|
(Trading Symbol) |
|
(Name of exchange on which registered) |
Voting
Common Stock, par value $0.0001 per share |
|
JSPR |
|
The
Nasdaq Stock Market LLC |
Redeemable
Warrants, each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50 |
|
JSPRW |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
5.07. Submission of Matters to a Vote of Security Holders.
On
June 23, 2022, Jasper Therapeutics, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders (the “Meeting”).
At the Meeting, a total of 19,415,543 shares of the
Company’s voting common stock, or approximately 53% of the 36,579,906 shares
of the Company’s voting common stock issued and outstanding as of April 26, 2022,
the record date for the Meeting, were represented in person or by proxy.
At
the Meeting, the Company’s stockholders considered two proposals, each of which is described in more detail in the Company’s
definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2022.
Set
forth below is a brief description of each matter voted upon at the Meeting and the voting results with respect to each matter.
Proposal
No. 1: To elect two Class I directors
to serve until the 2025 annual meeting of stockholders and until their successors are duly elected and qualified.
Director
Nominee |
|
Votes
For |
|
Votes
Withheld |
|
Broker
Non-Votes |
Kurt
von Emster |
|
17,769,058 |
|
324,016 |
|
1,322,469 |
Lawrence
Klein, Ph.D. |
|
17,890,093 |
|
202,981 |
|
1,322,469 |
Proposal
No. 2: To ratify the appointment of PricewaterhouseCoopers
LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2022.
Votes
For |
|
Votes
Against |
|
Abstentions |
19,074,569 |
|
340,973 |
|
1 |
Item
9.01. Financial Statements and Exhibits.
(d) Exhibits.
104 |
Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
JASPER THERAPEUTICS, INC. |
|
|
|
Date: June 27, 2022 |
By: |
/s/ Jeet Mahal |
|
|
Name: Jeet Mahal |
|
|
Title:
Chief Operating Officer and
Chief Financial Officer |
2
Jasper Therapeutics (NASDAQ:JSPR)
Historical Stock Chart
From May 2024 to Jun 2024
Jasper Therapeutics (NASDAQ:JSPR)
Historical Stock Chart
From Jun 2023 to Jun 2024